$15.83 million was raised by Reviva Pharmaceuticals following the successful placement and issuance of its unregistered equity securities. A total of forty-seven investors participated to the non-brokered placement which started almost two weeks ago. Two previous unregistered financing rounds raised an estimated $19.66 million.
Reviva Pharmaceuticals develops new drugs for the central nervous system, metabolic, cardiovascular, inflammation and pain indications. Therapeutic drugs are developed by using an integrated chemical genomics approach and proprietary chemistries.
The company, headquartered in San Jose CA, is led by Laxminarayan Bhat (President and CEO). Reviva Pharmaceuticals elected to keep its revenues undisclosed.
The company has raised an estimated total of $35.5 million via private unregistered security offerings.
Company: Reviva Pharmaceuticals
Amount offered: $15.83 million
Amount placed: $15.83 million
First sale: 06-12-2014
Data as of: 06-25-2014